d******8
发帖数: 1972 | 1 好像没有什么影响。
http://finance.yahoo.com/news/amarin-reports-first-quarter-2012
BEDMINSTER, N.J., and DUBLIN, Ireland, May 8, 2012 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical
company focused on cardiovascular disease, today announced financial results
for the quarter ended March 31, 2012 and provided an update on company
operations.
Amarin noted the following highlights since the quarter ended December 31,
2011:
Received Notice of Allowance for paten... 阅读全帖 |
|
n**********8
发帖数: 340 | 2 【 以下文字转载自 Chinook 俱乐部 】
发信人: niuniuzhu168 (妞妞), 信区: Chinook
标 题: Four Drug Stocks Facing FDA Approval Decisions in July
发信站: BBS 未名空间站 (Wed Jul 4 00:08:43 2012, 美东)
BOSTON (TheStreet) -- Four FDA drug approval decisions in July -- headlined
by another weight-loss drug and a prescription fish oil pill with
blockbuster potential -- will keep biotech investors busy in what is
normally one of the sector's slower months.
Vivus(VVUS_) is expected to learn the fate of its weight-loss pill Qnexa on
Tu... 阅读全帖 |
|
f****X
发帖数: 64 | 3 Lovaza的市场渗透率仅仅是5%左右，虽然能降低甘油三酯，但副作用是升高了LDL，这一
副作用影响了它的使用人数。
AMR101，降低了甘油三酯，4g组也能降低LDL，再加上Anchor trial的适用人群，AMR101
能达到10倍的销售量，可能性还是很大的。
AMR101 Outcomes Study subjects：elevated triglyceride levels and
either coronary heart disease or risk factors for coronary heart disease。仅
仅在美国的病人数量就达的70 Million。日本的JELIS study提示AMR101 Outcomes
Study positive有很大可能性。当然这是六年以后的事情了。 |
|
d******8
发帖数: 1972 | 4 今天一早由于新药网站提前泄露，导致今天一早大涨快16，现在回落到15.35
Amarin addressed the slip in a securities filing Thursday, blaming a third
party for the mishap:
On July 19, 2012, information related to AMR101, Amarin Corporation plc’s (
“Amarin”) lead product candidate, and its pending regulatory review with
the U.S. Food and Drug Administration (“FDA”) was inadvertently published
through a draft website that is under design by third parties on behalf of
Amarin. The information was outdated and should not be relied upon ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 5 Amarin Heart-Drug Patent Application Rejected By US Patent Office
7 minutes ago - DJNF
By Peter Loftus
Of DOW JONES NEWSWIRES
The U.S. Patent & Trademark Office rejected Amarin Corp.'s (AMRN)
application for a patent covering an experimental heart drug derived from
fish oil, causing the Dublin-based company's American depositary shares to
fall as much as 9.5% Wednesday.
The drug, code-named AMR101, would treat high levels of triglycerides, a
fatty substance in the blood linked to risk for heart ... 阅读全帖 |
|
d******8
发帖数: 1972 | 6 February 13, 2012 8:10 AM EST
Amarin Corporation plc (Nasdaq: AMRN) announced today that it was informed
by the U.S. FDA that no advisory committee meeting will be scheduled in
connection with the FDA's review of the NDA seeking approval for the use
AMR101 in the treatment of patients with very high triglycerides (≥500mg/dL
), the company's lead product candidate. The FDA has previously assigned a
Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion
of its review of the AM... 阅读全帖 |
|
k****h
发帖数: 944 | 7 谢谢主席，多大幅度的调整？
”07/26/2012 Amarin Corp Plc AMRN AMR101 (NDA) FDA decision on AMR101 as
treatment for very high triglycerides (greater than or equal to 500mg/dL)“
持股至26号前几天吗？ |
|
T*C
发帖数: 5492 | 8 Shares of Amarin (AMRN +2.1%) return to earth since spiking higher earlier
this morning after its marketing website inadvertently circulated a report
that Amarin's AMR101, or Vascepa, will be approved. The company acknowledged
the error, saying that says no determination on AMR101 NDA has yet been
made by the FDA, adding that information on the site was outdated and should
not be relied on. |
|
J********e
发帖数: 341 | 9 没看到AMR101会增高HDL-C，而且增高HDL-C对心脏无益应该只是speculation，是对
Niaspan不work的猜
测。
我不知道有没有遗漏关于AMR101对HDL-C level作用的数据，我在他们在National
Lipid Association 2011
的数据上没看到。
-C |
|
d******8
发帖数: 1972 | 10 AMRN Market Currents more » Tuesday 11:38 AM Amarin (AMRN +6.6%) jumps
after Jefferies (Buy) says it has learned the company would prefer either
to sell itself, or commercialize its AMR101 drug on its own, than to enter
into a royalty-bearing partnership for AMR101. Management is said to be
concerned about the challenges involved in negotiating a partnership |
|
p********e
发帖数: 1960 | 11 盘前有消息，说FDA不开Advisory Meeting, 难道是说药要么obvious好到一定程度，或
是差到一定程度？我宁愿相信是前者...
t it was informed by the U.S. Food and Drug Administration (FDA) that no
advisory committee meeting will be scheduled in connection with the FDA's
review of the New Drug Application (NDA) seeking approval for the use AMR101
in the treatment of patients with very high triglycerides (greater than or
equal to 500mg/dL), the company's lead product candidate. The FDA has
previously assigned a Prescription Drug User Fee Act (PDUF... 阅读全帖 |
|
V**D
发帖数: 2869 | 12 【 以下文字转载自 HuNan 讨论区 】
发信人: VitD (VitD), 信区: HuNan
标 题: 吃多少鱼油才能降血脂
发信站: BBS 未名空间站 (Mon Jan 7 17:56:32 2013, 美东)
今早上班途中听洛城AM1300的广播，其中医学方面的节目主要讲了补充维生素D以及鱼
油的重要性。鱼油可能是最早出现的保健品，早年回国带得最多的就是鱼油，现在反而
很少带回去了。鱼油对于降低血脂到底有多少帮助，我也不是十分清楚。
鱼油的有效成分是Omega-3 fattic acid, 包括EPA 和DHA,具有减少身体中的炎症和降
低血脂的功能。午饭时我跟同事聊天谈到鱼油，她说医生建议吃高Omega-3含量（900）
左右的鱼油才有用，我这才想起以前一直关注的一家专门生产降血脂药物的公司（
Amarin)的产品AMR101,其成分就是EPA Ethyl ester( Omega-3 Acid的乙酯）。在网上
一查得知吃2000 mg的计量可以降低10%的血脂，如果按这样一个标准来算，每天吃两颗
高Omega-3（900）的鱼油，就可以达到相同的效果。如果血脂很高，... 阅读全帖 |
|
f****X
发帖数: 64 | 13 AMR101是鱼油里面提取的纯度大于96%的EPA
GSK的Lovaza也是鱼油里面提取的EPA+DHA，如果就是鱼油的话，为什么Lovaza去年作为
处方药卖了接近$1 billion？ |
|
f****X
发帖数: 64 | 14 AMR101的专利保护时间的长短，决定了这个药值多少钱。CEO说有人出$15,他们觉的这
个价钱太低了，不能接受。
如果Anchor trial的indication包括在新药的labelling中的话，这个价是严重低估了
。所以这次NDA 包括了Anchor的data，对AMRN是很大的利好消息。 |
|
c*****1
发帖数: 25 | 15 请问这个专利pending在什么地方查？一般从申请到批准与否需要多长时间？以前AMRN
不是提过AMR101的专利保护至少到2021年吗？难道只是一个估计，并没有批下来. |
|
c*****1
发帖数: 25 | 16 谢谢，刚看了一下，里面只有已经批准的药，没查到AMR101啊？是我关键字用的不对还
是这种待批准的在另外的地方查？ |
|
c*****1
发帖数: 25 | 17 Outcome study按计划要2012年底才能招到50%的病人， 按原来与FDA谈的条件，那时候
才能递基于ANCHOR trial的NDA, 九月份能递的应该只是MARINE trial的适用病人群。
但Lovaza当年的公司卖给GSK是$1.65 billion， AMRN就是不考虑ANCHOR trial什么时
候递NDA也至少值这个价。
这一
AMR101 |
|
u********w
发帖数: 599 | 18 google "uspto pair".不过不熟的话不太好查、
AMR101目前没issue的专利。有个composition application现在离issuing最近。如果issue了2021 expire。他们还有三到四个method of use application， 如果issue了2029 expire。
这个composition application 如果issue的话，对股价会是冲25 PPS 的major catalyst。我是狂赌了。
AMRN |
|
K********g
发帖数: 9389 | 19 AMRN，大家都知道哦，AMR101，主要用于心脏病的，效果很好。唯一的缺点是Patent没
申请下来的问题。不过药明年被FDA批准的问题不是太大。
IMGN，很好，药TP，癌症的福音，估计批准的可能性极大。明年应该会申请NDA
ARIA，癌症药，几次的临床效果都不错。明年应该会申请NDA。 |
|
l**********y
发帖数: 2050 | 20 ☆─────────────────────────────────────☆
KeepBuying (雁过留声) 于 (Wed Dec 7 10:47:38 2011, 美东) 提到:
AMRN, IMGN, ARIA.
医药股风险大哦，小心哦。亏了别找我，赢了也别给我发包子
☆─────────────────────────────────────☆
dayandnig1 (蝶来风有致) 于 (Wed Dec 7 11:09:53 2011, 美东) 提到:
铁牛有啥分析，分享一下呗
☆─────────────────────────────────────☆
KeepBuying (雁过留声) 于 (Wed Dec 7 11:17:03 2011, 美东) 提到:
AMRN，大家都知道哦，AMR101，主要用于心脏病的，效果很好。唯一的缺点是Patent没
申请下来的问题。不过药明年被FDA批准的问题不是太大。
IMGN，很好，药TP，癌症的福音，估计批准的可能性极大。明年应该会申请NDA
ARIA，癌症药，几次的临床效果都不错。明年应该会... 阅读全帖 |
|
l**********y
发帖数: 2050 | 21 KeepBuying (雁过留声) 于 (Wed Dec 7 11:17:03 2011, 美东) 提到:
AMRN，大家都知道哦，AMR101，主要用于心脏病的，效果很好。唯一的缺点是Patent没
申请下来的问题。不过药明年被FDA批准的问题不是太大。
IMGN，很好，药TP，癌症的福音，估计批准的可能性极大。明年应该会申请NDA
ARIA，癌症药，几次的临床效果都不错。明年应该会申请NDA。
───────────────────────────────────
KeepBuying (雁过留声) 于 (Wed Dec 7 11:28:16 2011, 美东) 提到:
我个人认为AMRN和IMGN
────────────────────────────────────
KeepBuying (雁过留声) 于 (Wed Dec 7 11:42:10 2011, 美东) 提到:
不是Pump，是年初宣布药效，好得很，所以股价翻倍了，后来因为Patent的问题，并且大盘也不争气，所以就下来了。现在价格还可以哦。
────────────────────────────... 阅读全帖 |
|
d******8
发帖数: 1972 | 22 好消息还是坏消息？
Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA
for AMR101 |
|
V**D
发帖数: 2869 | 23 今早上班途中听洛城AM1300的广播，其中医学方面的节目主要讲了补充维生素D以及鱼
油的重要性。鱼油可能是最早出现的保健品，早年回国带得最多的就是鱼油，现在反而
很少带回去了。到底吃多少鱼油对于降低血脂有帮助，我也不是十分清楚。
鱼油的有效成分是Omega-3 fattic acid, 包括EPA 和DHA,具有减少身体中的炎症和降
低血脂的功能。午饭时我跟同事聊天谈到鱼油，她说医生建议吃高Omega-3含量（900）
左右的鱼油才有用，我这才想起以前一直关注的一家专门生产降血脂药物的公司（
Amarin)的产品AMR101,其成分就是EPA Ethyl ester( Omega-3 Acid的乙酯）。在网上
一查得知吃2000 mg的计量可以降低10%的血脂，如果按这样一个标准来算，每天吃两颗
高Omega-3（900）的鱼油，就可以达到相同的效果。如果血脂很高，那要吃4颗才有更
好的效果。 |
|
V**D
发帖数: 2869 | 24 今早上班途中听洛城AM1300的广播，其中医学方面的节目主要讲了补充维生素D以及鱼
油的重要性。鱼油可能是最早出现的保健品，早年回国带得最多的就是鱼油，现在反而
很少带回去了。到底吃多少鱼油对于降低血脂有帮助，我也不是十分清楚。
鱼油的有效成分是Omega-3 fattic acid, 包括EPA 和DHA,具有减少身体中的炎症和降
低血脂的功能。午饭时我跟同事聊天谈到鱼油，她说医生建议吃高Omega-3含量（900）
左右的鱼油才有用，我这才想起以前一直关注的一家专门生产降血脂药物的公司（
Amarin)的产品AMR101,其成分就是EPA Ethyl ester( Omega-3 Acid的乙酯）。在网上
一查得知吃2000 mg的计量可以降低10%的血脂，如果按这样一个标准来算，每天吃两颗
高Omega-3（900）的鱼油，就可以达到相同的效果。如果血脂很高，那要吃4颗才有更
好的效果。 |
|
X*****s
发帖数: 2767 | 25 想和你具体讨论一下AMRN，
Amarin's AMR101 Statistically Significant Reductions in Triglycerides at
Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
（April 18, 2011)
但是昨天出的一个消息“Abbott down after NIH halts Niaspan study”，里面提到
“In a study follow-up, participants who took Niaspan and simvastatin had
increased HDL cholesterol and lowered triglyceride levels compared to
participants who took a statin alone. But the combination treatment failed
to reduce heart attacks, strokes, hospita... 阅读全帖 |
|
y*****l
发帖数: 5997 | 26 10 Stocks That Should See Gains This Week
by: Brian Nichols August 15, 2011
ALU, AMRN, BZ, CVI, GM, GT, LULU, RES, SIRI, URBN
http://seekingalpha.com/article/287310-10-stocks-that-should-se
Amarin Corporation (AMRN) gained 20% over the last 3 days still leaving a
loss of nearly 7% in one month. This company has seen yearly gains in excess
of 430% as its lead drug AMR101 has investors very excited. The company
surpassed all levels of clinical trials including two pivotal phase three
programs... 阅读全帖 |
|
y*****l
发帖数: 5997 | 27 22 Hot Drugs Facing FDA Approval in 2012
By Adam Feuerstein 11/29/11 - 08:55 AM EST
BOSTON (TheStreet) -- Here's your first look at the biotech and
pharmaceutical companies with pending FDA drug approval decisions in 2012.
The calendar on the following pages captures nearly two-dozen U.S.
regulatory events -- FDA drug approvals and advisory panels -- expected
between December 2011 and July 2012. As every savvy biotech investor and
trader knows, the volatility in biotech and drug stocks ramps sig... 阅读全帖 |
|
y*****l
发帖数: 5997 | 28 【 以下文字转载自 Stock 讨论区 】
发信人: KeepBuying (雁过留声), 信区: Stock
标 题: Re: 2012年的明星医药股，大家别错过哦
发信站: BBS 未名空间站 (Wed Dec 7 11:17:03 2011, 美东)
AMRN，大家都知道哦，AMR101，主要用于心脏病的，效果很好。唯一的缺点是Patent没
申请下来的问题。不过药明年被FDA批准的问题不是太大。
IMGN，很好，药TP，癌症的福音，估计批准的可能性极大。明年应该会申请NDA
ARIA，癌症药，几次的临床效果都不错。明年应该会申请NDA。 |
|
l**********y
发帖数: 2050 | 29 【 以下文字转载自 Stock 讨论区 】
发信人: littleshelly (littleshelly), 信区: Stock
标 题: [合集] 2012年的明星医药股，大家别错过哦
发信站: BBS 未名空间站 (Sat Dec 10 19:46:20 2011, 美东)
☆─────────────────────────────────────☆
KeepBuying (雁过留声) 于 (Wed Dec 7 10:47:38 2011, 美东) 提到:
AMRN, IMGN, ARIA.
医药股风险大哦，小心哦。亏了别找我，赢了也别给我发包子
☆─────────────────────────────────────☆
dayandnig1 (蝶来风有致) 于 (Wed Dec 7 11:09:53 2011, 美东) 提到:
铁牛有啥分析，分享一下呗
☆─────────────────────────────────────☆
KeepBuying (雁过留声) 于 (Wed Dec 7 11:17:03 2011, 美东) 提到... 阅读全帖 |
|
